ANI Pharmaceuticals, Inc. ANIP
71.65 USD -0.63 (-0.87%)
At closeNov 4, 2026, 4:02 PM EST
72.00 +0.35 +0.49%
After hours · Nov 4, 4:02 PM ET
71.36 Day range 74.00
69.58 52-week range 95.57
- YTD
- -9.23%
- 1 year
- -24.16%
Analyst view
Consensus: buy
Buy
Price target (mean) 105.78 +47.6% upside
Now 71.65
- Target (low)
- 85.00
- Target (mean)
- 105.78
- Target (high)
- 121.00
Ratings (0m) 9 7 buy · 2 hold · 0 sell
- Strong buy3
- Buy4
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 9
- 1 month ago 9
- 2 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 2.18 | 2.02 – 2.33 | 2.04 | +6.9% | 280.20M | +23.0% | 9 |
| Next quarter | 2.82 | 2.57 – 2.97 | 2.33 | +21.0% | 319.27M | +29.2% | 9 |
| Current year | 9.26 | 9.17 – 9.37 | 7.89 | +17.4% | 1.10B | +24.9% | 9 |
| Next year | 10.13 | 9.46 – 10.47 | 9.26 | +9.3% | 1.22B | +10.8% | 9 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | Initiated | — | Perform |
| Aug 10, 2026 | Guggenheim | Maintained | Buy | Buy |
| Aug 10, 2026 | Canaccord Genuity | Maintained | Hold | Hold |
| Jul 17, 2026 | Canaccord Genuity | Initiated | — | Hold |
| Jul 10, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Jan 16, 2026 | Guggenheim | Maintained | Buy | Buy |
| Dec 9, 2025 | Barclays | Initiated | — | Overweight |
| Nov 10, 2025 | Guggenheim | Maintained | Buy | Buy |
| Oct 9, 2025 | Truist Securities | Maintained | Hold | Hold |
| Sep 24, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Sep 17, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 8, 2025 | Guggenheim | Maintained | Buy | Buy |
| Aug 11, 2025 | Truist Securities | Maintained | Hold | Hold |
| Aug 8, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 10, 2025 | HC Wainwright & Co. | Initiated | — | Buy |
| May 12, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Apr 21, 2025 | Truist Securities | Maintained | Hold | Hold |
| Apr 11, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Mar 17, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 14, 2025 | Jefferies | Initiated | — | Buy |
| Mar 12, 2025 | JP Morgan | Initiated | — | Overweight |
| Mar 5, 2025 | Guggenheim | Maintained | Buy | Buy |
| Mar 3, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 11, 2024 | Leerink Partners | Initiated | — | Outperform |
| Nov 11, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 22, 2024 | Truist Securities | Maintained | Hold | Hold |
| Oct 11, 2024 | Piper Sandler | Initiated | — | Overweight |
| Sep 18, 2024 | Raymond James | Maintained | Outperform | Outperform |
| Sep 17, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 11, 2024 | Truist Securities | Downgrade | Buy | Hold |